Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
30 mars 2023 08h00 HE
|
Apollomics, Inc.
FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations
15 nov. 2022 08h00 HE
|
Apollomics, Inc.
FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.
14 sept. 2022 08h30 HE
|
Apollomics, Inc.
– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet...
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
26 juil. 2022 07h10 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, July 26, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc. To Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
12 janv. 2022 07h05 HE
|
Apollomics, Inc.
FOSTER CITY, Calif., SHANGHAI and HANGZHOU, China, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
04 janv. 2022 07h10 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
22 nov. 2021 07h10 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and SHANGHAI and HANGZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...
Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial
30 sept. 2021 07h10 HE
|
Apollomics, Inc.; Edison Oncology Holding Corp.
MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies...
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
10 août 2021 07h10 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China and SHANGHAI, China, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of...
Apollomics Inc. Announces Official Opening of Shanghai Branch
20 mai 2021 10h19 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and SHANGHAI and HANGZHOU, China, May 20, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...